ScholarIQanswers from OpenAlex & ORCID
Teru Hideshima
ResearcherPublications, citations & collaboration network
Teru Hideshima is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Teru Hideshima have?
ScholarIQindexed works
Teru Hideshima has 1,057 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Teru Hideshima have?
ScholarIQcitation count
Teru Hideshima has 54,225 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Teru Hideshima?
ScholarIQh-index
Teru Hideshima has an h-index of 122 in OpenAlex.
What is the i10-index of Teru Hideshima?
ScholarIQi10-index
Teru Hideshima has an i10-index of 358 in OpenAlex.
What is the ORCID of Teru Hideshima?
ScholarIQorcid
The ORCID for Teru Hideshima is on the source record.
What is the OpenAlex record for Teru Hideshima?
ScholarIQopenalex
The OpenAlex for Teru Hideshima is on the source record.
What are the most-cited papers on Teru Hideshima?
ScholarIQmost cited works
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej Jakubowiak, Sundar Jagannath, Noopur Raje, David Avigan, Wanling Xie, Irene M. Ghobrial, Robert Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane Warren, Laura Lunde, Sarah Kaster, Carol Delaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie‐Lee Esseltine, Kenneth C. Anderson
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
Paul G. Richardson, Robert Schlossman, Edie Weller, Teru Hideshima, Constantine S. Mitsiades, Faith E. Davies, Richard LeBlanc, Laurence Catley, Deborah Doss, Kathleen Kelly, Mary McKenney, Julie Mechlowicz, Andrea Freeman, Reggie Deocampo, Rebecca L. Rich, Joan J. Ryoo, Dharminder Chauhan, Kathe Balinski, Jerome B. Zeldis, Kenneth C. Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust, Melissa Alsina, Robert Schlossman, S. Vincent Rajkumar, K.R. Desikan, Teru Hideshima, Nikhil C. Munshi, Kathleen Kelly-Colson, Deborah Doss, Mary McKenney, Svetlana G. Gorelik, Diane Warren, Andrea Freeman, Rebecca L. Rich, Anfang Wu, Marta Olesnyckyj, Kenton Wride, William S. Dalton, Jerome B. Zeldis, Robert Knight, Edie Weller, Kenneth C. Anderson
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Yu‐Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred Ian Lee, Klaus Podar, Teru Hideshima, Audie Rice, Anne van Abbema, Lynne Jesaitis, Ingrid W. Caras, Debbie A. Law, Edie Weller, Wanling Xie, Paul G. Richardson, Nikhil C. Munshi, Claire Mathiot, Hervé Avet‐Loiseau, Daniel Afar, Kenneth C. Anderson
Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Yutaka Okawa, Noopur Raje, Klaus Podar, Constantine S. Mitsiades, Nikhil C. Munshi, Paul G. Richardson, Ruben D. Carrasco, Kenneth C. Anderson